Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: A proposed classification scheme of interventions and meta-analysis of randomized controlled trials

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 4, 2001, Pages 917-930

  Sutherland, Susan E ^a,b   Browman, George P ^b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Clinical trials; Drug therapy; Head and neck neoplasms; Radiotherapy; Stomatitis

Indexed keywords

AMIFOSTINE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; BENZYDAMINE; BETA CAROTENE; CARBOPLATIN; CHLORHEXIDINE; COLISTIN; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROGEN PEROXIDE; MISOPROSTOL; POVIDONE IODINE; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SILVER NITRATE; SUCRALFATE; TOBRAMYCIN;

ARTICLE; CHEMOTHERAPY; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; HEAD AND NECK CANCER; HUMAN; LASER; LITERATURE; LOZENGE; META ANALYSIS; METHODOLOGY; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; TECHNIQUE; TREATMENT OUTCOME;

CONFIDENCE INTERVALS; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH MUCOSA; ODDS RATIO; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; STOMATITIS;

EID: 0035869710     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01456-5     Document Type: Article

References (120)

1. The effect of radiation on normal tissues of the head and neck
2. Oral complications
3. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck; The final report of a randomized trial
4. Prospective randomized trial comparing hyperfractioned versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma
5. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma; Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
6. Placebo controlled randomized trial of infusion flourouracil during standard radiotherapy in locally advanced head and neck cancer
7. Altered fractionation schedules
8. Mucositis as a biological process; A new hypothesis for the development of chemotherapy-induced stomatotoxicity
9. The biological basis for the attenuation of mucositis; The example of interleukin-11
10. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis
11. Mucosal protectants and their application for head and neck chemoirradiation
12. Prevention and management of oral mucositis induced by antineoplastic therapy
13. Guidelines for reading literature reviews
14. Empirical evidence of bias; Dimensions of methodologic quality associated with estimates of treatment effects in controlled trials
15. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analysis?
16. Assessing the quality of reports of randomized clinical trials; Is blinding necessary?
17. Scoring oral mucositis
18. Efficacy and safety of non-steroidal antiinflammatory drugs for cancer pain; A meta-analysis
19. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics
20. Quantitative synthesis in systematic reviews
21. Meta-analysis in clinical trials
22. Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors
23. Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma
24. Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial
25. Radiotherapy of head-neck neoplasms; Prevention of inflammation of the mucosa by sucralfate treatment
26. Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy
27. Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer-prevention of stomatitis and hematopoietic impairment
28. Use of prostin E2 in the treatment of stomatitis caused by radiotherapy
29. Prevention of radiochemotherapy-induced mucositis. Value of the prophylactic mouth rinsing with PVP-iodine solution
30. Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity
31. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy
32. Comparative evaluation of benzydamine oral rinse in children with anti-neoplastic-induced stomatitis
33. The use of benzydamine HCL for the management of cancer therapy-induced mucositis; Preliminary report of a multicentre study
34. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis; A randomized double-blind trial
35. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole
36. Sucralfate for radiation mucositis; Results of a double-blind randomized trial
37. A clinical study of benzydamine for the treatment of radiotherapy-induced mucositis of the oropharynx
38. Treatment of radiation- and chemotherapy-induced stomatitis
39. Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer
40. Local benefits of prostaglandin E2 in radiochemotherapy-induced oral mucositis
41. A new administration schedule for amifostine as a radioprotector in cancer therapy
42. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy
43. Benzydamine HCL in prevention of oropharyngeal mucositis in radiation therapy; Literature review and clinical study
44. Protection from radiation-induced oral mucositis by misoprostal, a prostaglandin E1 analog; A placebo-controlled double-blind clinical trial
45. Radiation mucositis; A new approach to the prevention and treatment
46. Amifostine; A radioprotector in locally advanced head and neck tumors
47. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis
48. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy
49. Sucralfate mouth washing in the prevention of radiation-induced mucositis; A placebo-controlled double-blind randomized study
50. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study
51. Sucralfate in the prevention of radiation-induced oral mucositis
52. Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers
53. A prospective pilot study on the effect of sucralfate mouth-swishing in reducing stomatitis during radiotherapy of the oral cavity
54. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial
55. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy
56. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis
57. Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer
58. Effects of stimulated repopulation on oral mucosa during conventional radiotherapy
59. Management of mucositis in oral irradiation
60. Efficacy and safety of granulocyte macrophage colony-stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma
61. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy
62. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during x-radiation therapy; A preliminary report
63. Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy
64. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis; a prospective randomized study
65. Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer
66. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers
67. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic radiation
68. Prevention of oral mucositis in radiation therapy; A controlled study with benzydamine hydrochloride rinse
69. Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis?
70. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis
71. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis
72. Povidone-iodine to prevent mucositis in patients during anti-neoplastic radiochemotherapy
73. Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients
74. Prevention of mucositis in irradiated head and neck cancer patients
75. Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis
76. The reduction of radiation mucositis by selective decontamination antibiotic pastilles; A placebo-controlled double-blind trial
77. A randomized trial of a non-absorbable antibiotic lozenge given to alleviate radiation-induced mucositis
78. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
79. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis; An interim look at a randomized, double-blind, placebo-controlled trial
80. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study
81. Amifostine-a radioprotector in locally advanced head and neck tumors
82. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
83. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer
84. Oral glutamine to alleviate radiation-induced oral mucositis; a pilot randomized trial
85. Effect of prophylactic sucralfate on stomatitis induced by cancer chemotherapy
86. Meta-analysis; Principles and procedures
87. Methodologic guidelines for systematic reviews of randomized controlled trials in health care from the Potsdam Consultation on meta-analysis
88. Gastrointestinal cytoprotection by prostaglandins
89. Mechanisms of action of sucralfate
90. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural and functional assessment in the rat
91. Sucralfate stimulation of gastric PGE2 synthesis-possible mechanism to explain its effective cytoprotective properties
92. Cytoprotection by prostaglandins
93. Current status of retinoids in chemoprevention of oral squamous cell carcinoma; An overview
94. Retinoid actions and implications for prevention and therapy of oral cancer
95. The effects of hydrogen peroxide rinses on the normal oral mucosa
96. Hematopoietic growth factors; Biology and clinical applications
97. Radiation esophagitis in the opossum; Radioprotection with indomethacin
98. Aspects of the mechanism of action of benzydamine
99. The effect of irradiation upon the bacterial flora in patients with head and neck cancer
100. Oral findings in irradiated edentulous patients
101. Bias in meta-analytic research
102. Selecting the language of the publications included in a meta-analysis; Is there a tower of babel bias?
103. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
104. The potential of amifostine; From cytoprotectant to therapeutic agent
105. Prophylactic glutamine protects the intestinal mucosa from radiation injury
106. Biostimulation of wound healing by lasers; Experimental approaches in animal models and in fibroblast cultures
107. Biostimulation of wound healing in vivo by a helium-neon laser
108. Control of connective tissue metabolism by lasers; Recent developments and future prospects
109. New clinical applications of granulocyte-macrophage colony-stimulating factor
110. Comparison of the in vivo and in vitro antibacterial properties of povidone-iodine and chlorhexidine gluconate mouthrinses
111. Microbiological effects of mouthrinses containing antimicrobials
112. Retention of chlorhexidine in the human oral cavity